JOP20250072A1 - المركبات ثلاثية الحلقات واستخداماتها - Google Patents

المركبات ثلاثية الحلقات واستخداماتها

Info

Publication number
JOP20250072A1
JOP20250072A1 JOJO/P/2025/0072A JOP20250072A JOP20250072A1 JO P20250072 A1 JOP20250072 A1 JO P20250072A1 JO P20250072 A JOP20250072 A JO P20250072A JO P20250072 A1 JOP20250072 A1 JO P20250072A1
Authority
JO
Jordan
Prior art keywords
those compounds
tricyclic compounds
compounds
pharmaceutically acceptable
compound
Prior art date
Application number
JOJO/P/2025/0072A
Other languages
English (en)
Inventor
Vincent Bordas
Sisi Zhang
Yong Zhang
Frederic Zecri
Ross Strang
Niko Schmiedeberg
Joseph Schoepfer
Markus Furegati
Wei Li
Fabio Lima
Fatma Limam
Henrik Moebitz
Sandro Nocito
Jacques Hamon
Ziyue Hong
Juergen Hans-Hermann Hinrichs
Xinkan Yang
Huangchao Yu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20250072A1 publication Critical patent/JOP20250072A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يقدم الاختراع الحالي مركبًا أو أحد أملاحه المقبولة صيدلانيًا بالصيغة (I): حيث إن R1 وR2 وR3 وx وR4 وR5 وy وR وM وW وL وV وT وY وJ وK وA هي كما تم وصفها في هذا الطلب، والاستخدامات العلاجية لتلك المركبات، واستخدامات تلك المركبات كمواد كيميائية في البحث، وتركيبة صيدلانية وتركيبات تحتوي على تلك المركبات، وطرق تصنيع المركبات التي تم اختراعها.
JOJO/P/2025/0072A 2022-10-12 2025-04-10 المركبات ثلاثية الحلقات واستخداماتها JOP20250072A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2022124865 2022-10-12
EP22208192 2022-11-17
US202363494033P 2023-04-04 2023-04-04
CN2023108913 2023-07-24
PCT/IB2023/060166 WO2024079623A1 (en) 2022-10-12 2023-10-10 Tricyclic compounds and their uses

Publications (1)

Publication Number Publication Date
JOP20250072A1 true JOP20250072A1 (ar) 2025-04-10

Family

ID=88315575

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0072A JOP20250072A1 (ar) 2022-10-12 2025-04-10 المركبات ثلاثية الحلقات واستخداماتها

Country Status (17)

Country Link
US (1) US20240245694A1 (ar)
EP (1) EP4601746A1 (ar)
JP (1) JP2025536259A (ar)
KR (1) KR20250079023A (ar)
CN (1) CN120077048A (ar)
AR (1) AR130727A1 (ar)
AU (1) AU2023361889A1 (ar)
CL (1) CL2025001072A1 (ar)
CR (1) CR20250187A (ar)
DO (1) DOP2025000087A (ar)
IL (1) IL319660A (ar)
JO (1) JOP20250072A1 (ar)
MX (1) MX2025004220A (ar)
PE (1) PE20251323A1 (ar)
TW (1) TW202417450A (ar)
UY (1) UY40470A (ar)
WO (1) WO2024079623A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121443294A (zh) 2023-06-08 2026-01-30 林伯士瓦吉特公司 Wrn抑制剂
WO2025026382A1 (zh) * 2023-08-01 2025-02-06 海思科医药集团股份有限公司 一种氧代三并环类衍生物及其在医药上的应用
WO2025073792A1 (en) 2023-10-02 2025-04-10 Forx Therapeutics Ag Wrn inhibitory compounds
WO2025140518A1 (zh) * 2023-12-29 2025-07-03 勤浩医药（苏州）有限公司 稠环化合物、包含其的药物组合物及其用途
WO2025152932A1 (zh) * 2024-01-15 2025-07-24 上海齐鲁制药研究中心有限公司 一种三唑并嘧啶类衍生物、其制备方法和应用
WO2025162478A1 (en) * 2024-02-04 2025-08-07 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof
WO2025218781A1 (en) * 2024-04-19 2025-10-23 Insilico Medicine Ip Limited Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2025223396A1 (en) * 2024-04-22 2025-10-30 3H Pharmaceuticals Co., Ltd. Fused tricyclic compounds and methods of use thereof
WO2025232693A1 (en) * 2024-05-08 2025-11-13 Nuphase Therapeutics (Shanghai) Limited., Co. Novel compounds, compositions comprising the same and uses thereof
TW202604520A (zh) * 2024-05-16 2026-02-01 大陸商海思科醫藥集團股份有限公司 氧代三並環類衍生物及其在醫藥上的應用
WO2025237389A1 (zh) * 2024-05-17 2025-11-20 成都微芯药业有限公司 三环wrn抑制剂、其制备方法及其应用
TW202547509A (zh) * 2024-05-24 2025-12-16 大陸商浙江海正藥業股份有限公司 氮雜三環類衍生物及其製備方法和用途
WO2025247335A1 (en) * 2024-05-30 2025-12-04 Allorion Therapeutics Inc Compounds and use thereof as wrn inhibitors
WO2026003380A1 (en) 2024-06-28 2026-01-02 Forx Therapeutics Ag Wrn inhibitory compounds
WO2026012391A1 (zh) * 2024-07-10 2026-01-15 广州科恩泰生物医药科技有限公司 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2664433A1 (en) * 2006-08-29 2008-03-06 Trustees Of Boston University Therapeutic methods using wrn binding molecules
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CA3219799A1 (en) * 2021-05-26 2022-12-01 Novartis Ag Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn)

Also Published As

Publication number Publication date
IL319660A (en) 2025-05-01
CR20250187A (es) 2025-06-04
EP4601746A1 (en) 2025-08-20
AR130727A1 (es) 2025-01-15
UY40470A (es) 2024-05-15
WO2024079623A1 (en) 2024-04-18
CN120077048A (zh) 2025-05-30
PE20251323A1 (es) 2025-05-16
MX2025004220A (es) 2025-05-02
TW202417450A (zh) 2024-05-01
CL2025001072A1 (es) 2025-08-01
DOP2025000087A (es) 2025-06-15
JP2025536259A (ja) 2025-11-05
KR20250079023A (ko) 2025-06-04
US20240245694A1 (en) 2024-07-25
AU2023361889A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
MX2025004220A (es) Compuestos triciclicos y sus usos
MX389697B (es) Nuevos derivados de pirazolopirimidina.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
CL2009001980A1 (es) Combinacion farmaceutica que comprende un derivado de quinolina y uno o mas de otros agentes antimicobacterianos; composicion farmaceutica que la comprende; y uso para el tratamiento de una infeccion por una cepa de mycobacterium resistente a farmacos (divisional de la solicitud 1290-05).
UY28510A1 (es) Compuestos quimicos
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
CL2011000009A1 (es) Composicion farmaceutica que comprende un compuesto derivado de (diaza)- u (oxa-aza)-biciclo-octano en combinacion con un antibiotico de beta-lactamina; y el uso de la composicion para inhibir la produccion de beta-lactamasa en una terapia antibacteriana. (divisional de la solicitud 134-2003)
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CO2024007202A2 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
SA523442503B1 (ar) مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"